IDDI Comment on the FDA Draft Guidance on Expansion Cohorts
FDA Draft Guidance for Industry on the Use of Expansion Cohorts
IDDI has submitted a comment on the Food and Drug Administration (FDA) recent Draft Guidance for Industry regarding the use of expansion cohorts in first-in-human clinical trials.
| |
|